Cantargia (Cantargia AB); today announced new clinical results from two nadunolimab combination therapy trials in 54 patients. Positive signals of efficacy were documented in the key areas of ...
GenSight Biologics' lead product candidate, GS010, is in Phase III trials in Leber Hereditary Optic Neuropathy (LHON), a rare mitochondrial disease that leads to irreversible blindness in teens and ...
Frequent leg and foot cramps might signal underlying health problems requiring medical attention. While occasional cramps are common, persistent episodes ...
The Bcl-2 inhibitor venetoclax is highly effective and is another first- or second-line option even if this agent, like BTK inhibitors, also appears to require continuous dosing, said Stadtmauer, ...